A study published in ‘The New England of Medicine’ reveals how an antidiabetic helps fight obesity
New promise for the treatment of obesity. Tirazeptide, developed as a therapy against type 2 diabetes, may be an important pharmacological ally to combat overweight, given the results of a phase III, multicenter, randomized trial recently reported in The New England Journal of Medicine. Published, which is one of the most prestigious medicine. the magazines
According to the data of this work, which is compared three different doses of the drug versus placebo for 72 weeksThe therapy, given once a week, has been able to produce very significant weight loss. There was a 15% weight loss with the lowest dose (5 mg), a percentage that reached 21% in the group treated with the highest dose (15 mg).
It notes an editorial accompanying the work in the medical journal Weight Loss, is equal to that achieved by gastric bypass surgery,
Essay I didn’t get any side effects Concern associated with the drug, and only gastrointestinal symptoms, such as nausea or diarrhea, were reported.
Other positive ‘side effects’
The treatment, the researchers noted in the journal, also made it possible to achieve improve the size of the abdominal circumferenceBlood pressure, cholesterol or glucose metabolism.
work done 30. Follow-up of 2,539 individuals with a body mass index (BMI) greater than (considered obese) or at least 27 (considered overweight with a BMI of 25) if they also had an associated cardiovascular risk factor.
At the start of the investigation, 94.5% of participants had a BMI of at least 30, an average weight of 104.8 kg and a mean BMI of 38.
The group was given 5, 10 or 15 mg . was divided to receive treatment of To take the drug or a placebo during the 72 weeks of the study, funded by Eli Lilly, the pharmaceutical company responsible for the drug.
At the end of this period, the researchers found that 57% of participants in the 10 and 15 mg groups had achieved a weight loss of 19.5% and 20.9%, respectively, a percentage that had dropped to 3%. placebo group.
In the case of treatment with a dosage of 5 mg, The mean weight loss among the groups was 15%.
weight loss with therapy are very important and unusual for obesity medicine If the results are compared with those obtained in phase 3 trials with other drugs, the researchers explain in the journal Scientific.
according to the norms of